510(k) device
EpiWatch Monitoring System
Epiwatch, Inc. · Physiological Signal Based Seizure Monitoring System (POS, Class II) · First FDA decision Mar 7, 2025, newest Mar 7, 2025Epilepsy
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "EpiWatch"
MAUDE reports
0
Brand "EpiWatch", since 2015
PubMed studies
17
Mentioning "EpiWatch"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EpiWatch Monitoring System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K243515 · Decided Mar 7, 2025 · 114 days after receipt
Device type: Physiological Signal Based Seizure Monitoring System (POS) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "EpiWatch", any status and sponsor, newest update first.
EpiWatch, Inc.Not on our public-company list
NCT05059002 · 242 participants · Start Sep 20, 2021 · Primary completion Oct 31, 2023
Device: Physiological signal monitoring and seizure detection · For: Epilepsy, Tonic-Clonic
Sites: Baltimore, Maryland
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EpiWatch", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code POS
4 reports: 2 malfunction, 2 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "EpiWatch"[tiab]. The summary above synthesizes these.
- Using open-source intelligence to identify early signals of COVID-19 in Indonesia.
Thamtono Y, Moa A, MacIntyre CR · Western Pac Surveill Response J · 2021
- Could it be monkeypox? Use of an AI-based epidemic early warning system to monitor rash and fever illness.
Hutchinson D, Kunasekaran M, Quigley A, et al. · Public Health · 2023
- Seizure triggers identified postictally using a smart watch reporting system.
Ge A, Gutierrez EG, Wook Lee S, et al. · Epilepsy Behav · 2022Research Support, Non-U.S. Gov't
- Preventing the next pandemic: Use of artificial intelligence for epidemic monitoring and alerts.
MacIntyre CR, Lim S, Quigley A · Cell Rep Med · 2022Research Support, Non-U.S. Gov't
- Use of Open-Source Epidemic Intelligence for Infectious Disease Outbreaks, Ukraine, 2022.
Kannan A, Chen R, Akhtar Z, et al. · Emerg Infect Dis · 2024
- Global Epidemiology of Outbreaks of Unknown Cause Identified by Open-Source Intelligence, 2020-2022.
Honeyman D, Gurdasani D, Notaras A, et al. · Emerg Infect Dis · 2025
- Using Open-Source Intelligence to Detect Early Signals of COVID-19 in China: Descriptive Study.
Kpozehouen EB, Chen X, Zhu M, et al. · JMIR Public Health Surveill · 2020Research Support, Non-U.S. Gov't
- Open-Source Intelligence for Detection of Radiological Events and Syndromes Following the Invasion of Ukraine in 2022: Observational Study.
Stone H, Heslop D, Lim S, et al. · JMIR Infodemiology · 2023
- Using EPIWATCH® open-source surveillance to describe the epidemiology of lumpy skin disease outbreaks in South and Southeast Asia (2022-2023).
Hutchinson D, Li B, Lim S, et al. · Aust Vet J · 2024
- Artificial intelligence in public health: the potential of epidemic early warning systems.
MacIntyre CR, Chen X, Kunasekaran M, et al. · J Int Med Res · 2023Review
- Global epidemiology of vaccine-derived poliovirus 2016-2021: A descriptive analysis and retrospective case-control study.
Lai YA, Chen X, Kunasekaran M, et al. · EClinicalMedicine · 2022
- The global epidemiology of botulism outbreaks from open-source intelligence, 2017-2024.
Honeyman DA, Heslop DJ, MacIntyre CR · Am J Emerg Med · 2026Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code POS.
- EpiMonitorEmpatica S.r.l. · 510(k) 2025
- SPEAC SystemBrain Sentinel, Inc. · 510(k) 2021
- EmbraceEmpatica S.r.l. · 510(k) 2018
- Nelli (Version 7.11)Neuro Event Labs OY · 510(k) 2025
- NightWatch+ USLivassured BV · 510(k) 2025
- CompanionLgch, Inc. · De Novo 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.